Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q1 Report 2021

May 6, 2021

Investor presentations

SVB Leerink Presentation Feb 24, 2021

Corporate Deck February 2021

Corporate Deck January 2021

JPM Presentation Jan 14, 2021

Investor Deck December 2020

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

1 2 3

Press Releases

ObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development

press release

September 10, 2014

Geneva, Switzerland, 10 September 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative…

Read more

ObsEva SA announced today it was granted JEDI status and European SME status

press release

July 23, 2014

Geneva, Switzerland, 23 July 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for…

Read more

ObsEva SA Announces Appointments to its Board of Directors and Scientific Advisory Board

press release

January 17, 2014

Geneva, Switzerland, 17 January 2014 – ObsEva, a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for…

Read more
1 57 58 59 60

General Meetings

ObsEva Annual General Meeting 2020

June 9, 2020

Read more

ObsEva Annual General Meeting 2019

May 8, 2019

Read more
1 2 3

Upcoming Events

Save the date: ObsEva Annual General Meeting May 28, 2021

Event


    Read more
     

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    ObsEva U.S. Office

    1 Financial Center

    Suite 2440 Boston, MA 02111

    +1 857 972 9364


    contact@obseva.ch

    Media Switzerland & Europe

    Shauna Dillon

    +41 (0)22 552 1550 Office

    +41 79 360 3533 Mobile

    shauna.dillon@obseva.ch

    Media United States

    Shauna Dillon

    +41 (0)22 552 1550 Office

    +41 (0)79 360 3533 Mobile

    shauna.dillon@obseva.ch

    Investor relations


    .


    Joyce Allaire

    +1 (617)-435-6602

    ir@obseva.ch

    Clinical studies




    clinicaltrials@obseva.ch

    HR Office

    Charlotte Cadoux


    charlotte.cadoux@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    shauna.dillon@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue